Utrecht, The Netherlands and Cambridge, MA, USA-based investment firm Gilde Healthcare held the final close of its €145m ($200m) transatlantic growth capital fund.
Gilde Healthcare III (GHC III) is backed by a mix of international corporate and institutional investors including public fund-of-funds, family offices, entrepreneurs and Gilde partners.
The fund targets investment in innovative businesses in home and digital health, medical devices, diagnostics and therapeutics both in the United States and in Europe.
It aims to make a total of twelve equity investments (of up to €15m each).
GHC III has already invested in:
– The Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson’s disease.
– Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions,
– iWalk which commercializes bionic prosthetics for lower leg amputees, and
– Definiens, a provider of image analysis software for digital pathology.